The FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 10-9 Thursday that a mandate is still needed to rule out an unacceptable increase in cardiovascular (CV) risk for type 2 diabetes drugs intended for glycemic control, regardless of whether a safety signal exists.